Septin-7 Antibody, Cell-Binding Assay, Spinal Fluid
Use
Detects septin-7 IgG by cell-binding assay using cerebrospinal fluid specimens, aiding in the diagnosis of autoimmune disease of the central nervous system. Septin-7 IgG positive patients may exhibit neurological phenotypes such as encephalopathy, myelopathy, encephalomyelopathy, painful myelopolyradiculopathy, and episodic ataxia. The presence of septin-7 IgG is also associated with cancer, and patients may respond positively to immunotherapy.
Special Instructions
Not provided.
Limitations
Negative results for septin-7 IgG by cell-binding assay do not rule out the possibility of neurological autoimmunity or cancer. The test's performance characteristics are consistent with CLIA requirements but it has not been cleared or approved by the FDA, indicating that it is labeled as an Analyte Specific Reagent (ASR) product.
New York Approved
Methodology
Immunoassay (Cell-Binding Assay)
Biomarkers
Septin-7
Protein
LOINC Codes
- 101466-1 - Septin-7 IgG CSF Ql CBA IFA
- 101466-1 - Septin-7 IgG CSF Ql CBA IFA
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
1.5 mL
Minimum Volume
Not provided
Container
Sterile vial
Collection Instructions
Only orderable as a reflex. For more information, see related tests (ENC2, MDC2, MAC1).
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |